BCL2 and breast cancer: Similarly, in solid cancers including rhabdomyosarcoma, breast cancer, SCLC and melanoma, synergistic killing was achieved, either through transcriptional up-regulation of pro-apoptotic BIM, NOXA, PUMA or BMF [134–139] or suppression of BCL-2 and/or BCL-XL expression [137,138,140,141].